Caribou Biosciences, Inc.

NASDAQ:CRBU

Biotechnology

Healthcare
$0.49 -2.74%

-$0.05 today

Market cap
$52.47M
Beta
2.33
P/E (TTM)
-1.1
EPS (TTM)
-$1.39
52W Low $1.20High $3.54

Volume 1.01M

Average 1.83M

CRBU Interest Income

Income earned on cash, deposits, and investments held by the company.

Caribou Biosciences, Inc.NASDAQ: CRBU

Interest Income · Q1 FY2026 · quarter ended Mar 2026

Interest income remains negative

Q1 FY2026 interest income was $0, compared with $0 a year earlier. Trailing-twelve-month interest income was $0. Over 3 fiscal years it compounded at +20.3% a year.

Context

  • Interest income amounted to 71.7% of revenue in FY2025, up 71.7 pp from a year earlier.
  • Interest income increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly interest income holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$8M— YoY
LTMMar 2026
$0— YoY
Interest Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR+20.3%——
5-year CAGR——
10-year CAGR——

Interest Income history

USD · from the income statement

Latest · FY2025
8M USD
Year-over-year change
—
4-year CAGR
+171.1%

Interest Income vs competitors

How CRBU compares with its peers on the latest reported figures

  • Peers report in different currencies, so interest income is compared through growth and share of revenue rather than absolute size.
  • Interest income amounts to 0.0% of revenue for CRBU, versus a peer median of 24.0%.
CRBU Competitors
Interest Income for CRBU and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ALLOAllogene Therapeutics, Inc.LTM Mar 2026$17.35M USD-14.3%+61.7%—
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026$8.9M USD-24.3%+82.0%12.9%
FHTXFoghorn Therapeutics Inc.LTM Mar 2026$7.8M USD-35.9%+15.5%27.6%
AARDAardvark Therapeutics, Inc. Common StockLTM Mar 2026$4.85M USD+39.2%+249.9%—
TNYATenaya Therapeutics, Inc.LTM Mar 2026$2.84M USD-27.6%+11.1%1262.2%
IVAInventiva S.A.FY2025€2.83M EUR+147.5%+93.6%63.1%
PYXSPyxis Oncology, Inc.LTM Mar 2026$2.83M USD-58.0%+9.3%20.4%
HUMAHumacyte, Inc.LTM Mar 2026$2.26M USD-39.6%-0.5%111.9%
CRBUCaribou Biosciences, Inc.LTM Mar 2026$0 USD—+20.3%0.0%
OBIOOrchestra BioMed Holdings, Inc.LTM Mar 2026$0 USD-100.0%—0.0%
PRLDPrelude Therapeutics IncorporatedLTM Mar 2026$0 USD——0.0%
Peer median (excluding CRBU) —-27.6%+38.6%24.0%

Competitors are the stored peer set for CRBU. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue9.6M13.85M34.48M9.99M11.16M
Cost of Revenue984K3.64M3.53M3.93M3.65M
Gross Profit8.61M10.21M30.95M6.07M7.51M
Gross Margin89.7%73.7%89.8%60.7%67.3%
Research & Development52.26M82.23M112.08M130.15M109.44M
Selling, General & Admin23.34M38.02M38.46M46.46M37.91M
Operating Expenses75.59M116.61M147.01M172.68M143.71M
Depreciation & Amortization984K3.64M3.53M3.93M3.65M
EBITDA(65.61M)(95.71M)(98.35M)(145.19M)(145.03M)
EBITDA Margin-683.6%-691.0%-285.3%-1452.7%-1299.7%
Operating Income(66.98M)(106.4M)(116.06M)(166.62M)(136.19M)
Operating Margin-697.8%-768.2%-336.6%-1667.2%-1220.5%
Interest Income148K4.6M10.7M08M
Interest Expense8K0000
Other Income / Expenses377K7.05M14.18M17.5M(12.48M)
Income Before Tax(66.6M)(99.35M)(101.88M)(149.11M)(148.68M)
Pre-Tax Margin-693.9%-717.3%-295.5%-1492.0%-1332.3%
Income Tax Expense321K70K193K(9K)(550K)
Net Income(66.92M)(99.42M)(102.07M)(149.11M)(148.13M)
Net Margin-697.3%-717.8%-296.1%-1491.9%-1327.4%
EPS (Basic)(1.11)(1.64)(1.38)(1.65)(1.59)
EPS (Diluted)(1.11)(1.64)(1.38)(1.65)(1.59)
Weighted Avg Shares60.26M60.8M73.81M90.32M93.39M
Weighted Avg Shares (Diluted)60.26M60.8M73.81M90.32M93.39M

Caribou Biosciences, Inc.

NASDAQ:CRBU

Intrinsic Alpha fair value

Locked

Current Price

$0.49

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.